Carl Zeiss Meditec, Inc. Ships 1,000th OPMI(R) Pentero(R) Surgical Microscope to Loyola University Health System
Neurological Surgery Department Receives Revolutionary Visualization System for Neurosurgery and Spine Surgery
DUBLIN, CA--(Marketwire - September 17, 2007) - Carl Zeiss Meditec, Inc. announced shipment of
its 1,000th OPMI Pentero Surgical Microscope since its worldwide market
launch three years ago. This revolutionary microscope platform, which was
developed for use during neuro and spinal surgery, offers physicians new
capabilities which enhance surgical workflow.
The Neurological Surgery Department at Loyola University Health System and
Thomas C. Origitano, M.D., Ph.D., FACS, professor of neurological surgery
and the department chairman, are recipients of the 1,000th OPMI Pentero
The introduction of the OPMI Pentero marked a significant change in how
surgical microscopes are defined. Rather than just a singular tool, the
approach of a surgical cockpit, that is also an expandable platform, was
created. Its innovative architecture, which has the ability to add
application modules and upgrades to the classical surgical microscope,
enhances its utility and clinical life.
The system features visualization and application solutions resulting from
direct physician input. These include a breakthrough intra-operative
fluorescence module that allows physicians to visualize, check and
interpret blood flow quickly, which is critical in cerebral aneurysm
Emerging hospital demand for digital workflow is met by an integrated
digital video chain and seamless connection into the hospital's information
and communication infrastructure.
"The concept of integrating a best-in-class surgical microscope with a
platform offering application modules, which enhance surgical workflow and
enable emerging fluorescence-based techniques, has been extremely well
received by our customers," said Dirk Brunner, vice president, sales and
marketing for Neuro, ENT and Office Group Products at Carl Zeiss Meditec.
"As a result, there is very high demand for the OPMI Pentero."
The OPMI Pentero microscope is sold and distributed worldwide and will be
showcased at the upcoming 57th annual meeting of the Congress of
Neurological Surgeons, in San Diego, Calif., September 15 - 20, 2007 (Booth
About Carl Zeiss Meditec
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading
medical technology companies. This market position is based on over 160
years of experience in optical innovation. The company has two primary
areas of activity: In the field of ophthalmology Carl Zeiss Meditec offers
integrated solutions for treating the four main eye diseases: vision
defects (refraction), cataracts, glaucoma and retinal disorders. Product
innovations range from basic systems such as slit lamps and fundus cameras
to standard setting diagnostic systems such as the Humphrey® Field
Analyzer, the Stratus OCT™ and the IOLMaster®, to surgical microscopes
and innovative treatment systems in refractive laser surgery.
In the field of neuro and ENT surgery, Carl Zeiss Meditec is the world's
leading provider of surgical microscopes and microsurgical visualization
solutions for a very broad range of applications, such as tumour and
vascular surgery in the head region and/or spinal surgery. The most recent
example of our innovative performance in the area of microsurgery is the
OPMI Pentero® visualization system, which allows efficient and ergonomic
Carl Zeiss Meditec's medical technology portfolio is rounded off by
visualization systems for doctors in private practice and promising future
technologies such as intraoperative radiation therapy, which allows the
targeted treatment of breast cancer and brain cancer directly during
Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in
Germany (Carl Zeiss Meditec Surgical GmbH and Carl Zeiss Meditec
Vertriebsgesellschaf mbH), the USA (Carl Zeiss Meditec, Inc., Dublin,
California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl
Zeiss Meditec Iberia S.A., Madrid) and France (Ioltech SAS, La Rochelle,
and Carl Zeiss Meditec France SAS, Le Pecq).
Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The
remaining 65 percent are held by Carl Zeiss, one of the world's leading
international groups engaged in the optical and opto-electronics industry.
For additional information, visit www.meditec.zeiss.com/usa.
Contact Information: Media Contact: